New Clinical Data Analyses Show Metreleptin Reduced Blood Glucose & Triglyceride Levels in Patients with Rare Forms of Lipody...
June 25 2012 - 2:30PM
Business Wire
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced
findings from an ongoing clinical study (expanded access protocol)
that shows treatment with metreleptin, an investigational
medication under evaluation for the treatment of diabetes and/or
hypertriglyceridemia (high levels of triglycerides in the
bloodstream) in patients with rare forms of inherited or acquired
lipodystrophy, reduced blood glucose and triglyceride levels. These
findings were presented today in two separate posters at the
Endocrine Society’s 94th Annual Meeting and Expo (ENDO) in Houston,
Texas.
Lipodystrophy is an “ultra-orphan” rare disease estimated to
affect a few thousand people worldwide, which often manifests with
an early age of onset, has life-threatening metabolic
complications, and for which there is a significant unmet medical
need as there are no approved drugs that effectively treat the
underlying cause(s) of the disease.
“The data analyses presented in patients with rare forms of
lipodystrophy show that metreleptin lowered blood glucose and
triglyceride levels regardless of leptin levels and associated
autoimmune diseases,” said Elif Oral, M.D., University of Michigan,
Ann Arbor, Michigan, and a principal investigator in the expanded
access protocol for metreleptin. “In patients with lipodystrophy,
fat typically accumulates in the blood and organs such as liver and
muscle, which can lead to life-threatening complications including
insulin-resistant diabetes and hypertriglyceridemia. If approved,
metreleptin would be the first therapy indicated specifically for
the treatment of diabetes and/or hypertriglyceridemia in patients
with inherited or acquired lipodystrophy.”
Findings from the first poster titled, “Metabolic Effects of
Metreleptin Treatment in Familial Partial Lipodystrophy (FPL),”
included data from an ongoing expanded access protocol of
metreleptin administration in patients with rare forms of inherited
or acquired lipodystrophy. This analysis included 19 patients with
diabetes and/or high triglyceride levels who were diagnosed
clinically with FPL, one of the major subtypes of lipodystrophy,
without using a threshold leptin level as an eligibility criterion.
Overall, A1C, a measure of average blood sugar over three months,
and triglyceride levels improved with metreleptin treatment, and
metabolic benefits were observed across a range of leptin levels.
In patients with A1C ≥7% (14/19), A1C decreased by 0.4±0.6% at six
months (n=10) and 1.0±0.7% at 12 months (n=7). In patients with
triglyceride levels ≥200 mg/dL at baseline (12/19), triglyceride
levels decreased by 31±28 mg/dL at six months (n=6) and 184±127
mg/dL at 12 months (n=5). While on metreleptin, 2 of 12 patients on
oral antidiabetic agents (OAD) were able to discontinue an OAD, and
4 of 9 patients on insulin reduced their insulin dose by 20% or
more. Metreleptin was generally well tolerated.
Findings from the second poster titled, “Metreleptin Treatment
in Acquired Generalized Lipodystrophy: Consistent Metabolic Effects
in Three Patients Presenting with Distinct Autoimmune Conditions,”
focused on three pediatric patients with acquired generalized
lipodystrophy (AGL) who were studied under the same expanded access
protocol. AGL is another major lipodystrophy subtype that is
commonly associated with autoimmune diseases. These three patients
with AGL also had active autoimmune disease, including juvenile
dermatomyositis, autoimmune hepatitis, or Graves’ disease (a form
of auto-immune thyroid disease). With metreleptin treatment, each
patient experienced substantial reductions in lipodystrophy-related
metabolic abnormalities, such as diabetes or high triglyceride
levels, with no evidence of worsening of their respective
autoimmune diseases.
About Lipodystrophy
Fat tissue is a major endocrine organ producing important
metabolic hormones such as leptin. People with lipodystrophy lack
the required fat tissue for normal metabolic function. This can be
partial, affecting select areas of the body, or generalized,
affecting nearly the entire body. A lack of fat tissue can lead to
relative deficiency of leptin.
Without adequate leptin function, the metabolic system, which
regulates food intake and the storage and break-down of dietary fat
and carbohydrates, falls out of balance. As a result, fat
accumulates in the blood and organs such as liver and muscle, which
can lead to life-threatening complications including
insulin-resistant diabetes and hypertriglyceridemia (high levels of
triglycerides in the bloodstream).
There are no approved drugs that address the underlying relative
leptin deficiency that is believed to contribute in large part to
the metabolic abnormalities that occur in lipodystrophy. Currently
available therapies for diabetes and hypertriglyceridemia are often
rendered marginally effective due to the severity of the condition.
More information on lipodystrophy can be found at
www.mylipodystrophy.com.
About Metreleptin
Metreleptin, an analog of the human hormone leptin, is a unique
potential therapy for certain metabolic disorders in patients with
rare forms of inherited or acquired lipodystrophy. Metreleptin is
believed to work in part by reducing fat accumulation in organs,
thereby improving insulin sensitivity. Clinical studies have been
conducted by investigators at the National Institutes of Health
(NIH) and other academic institutions in the U.S., Europe, and
Japan to determine whether metreleptin can improve glycemic control
and hypertriglyceridemia in patients with lipodystrophy.
In December 2010, Amylin initiated its rolling biologics license
application (BLA) submission to the U.S. Food and Drug
Administration (FDA) for the use of metreleptin to treat diabetes
and/or hypertriglyceridemia in pediatric and adult patients with
rare forms of lipodystrophy. In April 2012, Amylin submitted the
chemistry, manufacturing and controls section of the BLA. Amylin
recently announced that the FDA is seeking updated data from the
submitted clinical studies that remain ongoing. Amylin is committed
to responding in a timely fashion to enable the FDA to complete its
evaluation of the rolling BLA submission.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development,
and commercialization of innovative medicines. Amylin is committed
to delivering novel therapies that transform the way diabetes and
other metabolic disorders are treated. Amylin is headquartered in
San Diego, Calif. and has a commercial manufacturing facility in
Ohio. More information about Amylin Pharmaceuticals is available at
www.amylin.com.
This press release contains forward-looking statements about
Amylin, which involve risks and uncertainties. Our actual results
could differ materially from those discussed herein due to a number
of risks and uncertainties, including risks that metreleptin as a
potential treatment option for diabetes and/or hypertriglyceridemia
in patients with rare forms of lipodystrophy will not be approved
by the FDA; risks that the FDA will not accept the BLA for filing;
risks that our clinical trials will not be completed when planned,
may not replicate previous results, may not be predictive of real
world use or may not achieve desired end-points; risks that our
preclinical studies may not be predictive; and other risks inherent
in the drug development and commercialization process. These and
additional risks and uncertainties are described more fully in the
Company's recently filed Form 10-Q. Amylin disclaims any obligation
to update these forward-looking statements.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024